These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24561467)

  • 1. Modified regimen of etanercept for tumor necrosis factor receptor associated periodic syndrome (TRAPS) like illness.
    Dhanrajani A; Khubchandani RP
    Indian Pediatr; 2014 Jan; 51(1):55-7. PubMed ID: 24561467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept.
    Jesus AA; Oliveira JB; Aksentijevich I; Fujihira E; Carneiro-Sampaio MM; Duarte AJ; Silva CA
    Eur J Pediatr; 2008 Dec; 167(12):1421-5. PubMed ID: 18408954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment.
    Stojanov S; Dejaco C; Lohse P; Huss K; Duftner C; Belohradsky BH; Herold M; Schirmer M
    Ann Rheum Dis; 2008 Sep; 67(9):1292-8. PubMed ID: 18180277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A.
    Nowlan ML; Drewe E; Bulsara H; Esposito N; Robins RA; Tighe PJ; Powell RJ; Todd I
    Rheumatology (Oxford); 2006 Jan; 45(1):31-7. PubMed ID: 16287931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder.
    Hull KM; Drewe E; Aksentijevich I; Singh HK; Wong K; McDermott EM; Dean J; Powell RJ; Kastner DL
    Medicine (Baltimore); 2002 Sep; 81(5):349-68. PubMed ID: 12352631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept.
    Arkwright PD; McDermott MF; Houten SM; Frenkel J; Waterham HR; Aganna E; Hammond LJ; Mirakian RM; Tomlin PI; Vijaydurai PI; Cant AJ
    Clin Exp Immunol; 2002 Dec; 130(3):484-8. PubMed ID: 12452839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients.
    Drewe E; McDermott EM; Powell PT; Isaacs JD; Powell RJ
    Rheumatology (Oxford); 2003 Feb; 42(2):235-9. PubMed ID: 12595616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment with infliximab of a patient with tumor necrosis factor-associated periodic syndrome (TRAPS) who failed to respond to etanercept.
    Krelenbaum M; Chaiton A
    J Rheumatol; 2010 Aug; 37(8):1780-2. PubMed ID: 20675856
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome.
    Drewe E; Huggins ML; Morgan AG; Cassidy MJ; Powell RJ
    Rheumatology (Oxford); 2004 Nov; 43(11):1405-8. PubMed ID: 15316120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis.
    Kallinich T; Briese S; Roesler J; Rudolph B; Sarioglu N; Blankenstein O; Keitzer R; Querfeld U; Haffner D
    J Rheumatol; 2004 Dec; 31(12):2519-22. PubMed ID: 15570662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response.
    Aróstegui JI; Solís P; Aldea A; Cantero T; Rius J; Bahíllo P; Plaza S; Vives J; Gómez S; Yagüe J
    Eur J Pediatr; 2005 Jan; 164(1):13-6. PubMed ID: 15549379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: a case report and review of the literature.
    Chen YJ; Yu HH; Yang YH; Lau YL; Lee WI; Chiang BL
    J Microbiol Immunol Infect; 2014 Dec; 47(6):550-4. PubMed ID: 22921805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature.
    Cantarini L; Rigante D; Lucherini OM; Cimaz R; Laghi Pasini F; Baldari CT; Benucci M; Simonini G; Di Sabatino V; Brizi MG; Galeazzi M
    Int J Immunopathol Pharmacol; 2010; 23(3):701-7. PubMed ID: 20943039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new mutation causing autosomal dominant periodic fever syndrome in a Danish family.
    Weyhreter H; Schwartz M; Kristensen TD; Valerius NH; Paerregaard A
    J Pediatr; 2003 Feb; 142(2):191-3. PubMed ID: 12584543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement.
    Minden K; Aganna E; McDermott MF; Zink A
    Ann Rheum Dis; 2004 Oct; 63(10):1356-7. PubMed ID: 15361406
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment.
    Cantarini L; Lucherini OM; Galeazzi M; Fanti F; Simonini G; Baldari CT; Laghi Pasini F; De Martino M; Cimaz R
    Clin Exp Rheumatol; 2009; 27(5):890-1. PubMed ID: 19917181
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives.
    Cantarini L; Lucherini OM; Muscari I; Frediani B; Galeazzi M; Brizi MG; Simonini G; Cimaz R
    Autoimmun Rev; 2012 Nov; 12(1):38-43. PubMed ID: 22884554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study.
    Bulua AC; Mogul DB; Aksentijevich I; Singh H; He DY; Muenz LR; Ward MM; Yarboro CH; Kastner DL; Siegel RM; Hull KM
    Arthritis Rheum; 2012 Mar; 64(3):908-13. PubMed ID: 22006113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept].
    Boms S; Sehr T; Jappe U; Enk A
    Hautarzt; 2008 Aug; 59(8):653-5. PubMed ID: 18210001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome.
    Takada K; Aksentijevich I; Mahadevan V; Dean JA; Kelley RI; Kastner DL
    Arthritis Rheum; 2003 Sep; 48(9):2645-51. PubMed ID: 13130485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.